Target Hemoglobin Range in Most Anemic Chronic Kidney Disease Pre-Dialysis Patients Achieved With PROCRIT® (Epoetin alfa) Therapy Initiated Every Two Weeks
For the specific patient population, the USFDA-approved initiation dose of PROCRIT® is 50-100 Units/kg three times a week.
In the said study more than 88 percent of patients treated with PROCRIT 20,000 Units once every two weeks achieved a target hemoglobin (Hb) of between 11 and 12 grams per deciliter of blood (g/dL). The average Hb reached the target range by week six and stayed in that range for the remainder of the 28-week study.
PROCRIT® (Epoetin alfa), a product of Ortho Biotech Products, L.P. (4336966) is a prescription medication for the treatment of anemia in chronic kidney disease patients who are not on dialysis and is administered by injection of doctors or nurses.
Find more details from the press release.
Comment Preview